Intra-Cellular Therapies, Inc.
NasdaqGS:ITCI
$ 71.81
$-0.49 (-0.68%)
$ 71.81
$-0.49 (-0.68%)
End-of-day quote: 04/30/2024

Intra-Cellular Therapies financials at a glance

The revenue of Intra-Cellular Therapies is reported as 0.46437 billion Dollars in the fiscal year 2023. The earnings were -1.46 Dollars per share in 2023, which was 46.32 higher than 2022. And about -0.10851 billion Dollars are reported as free cash flow in the financials of Intra-Cellular Therapies 2023. No dividends were paid to the shareholders of the Intra-Cellular Therapies stock NasdaqGS:ITCI in the financial year 2023.

$464.37M
Revenue
$-1.46
Earnings Per Share
53.94%
Gross Margin %
$-,160.85M
Free Cash Flow
Revenue
464.37
Earnings Per Share
-1.46
Gross Margin %
53.94
Free Cash Flow
-,160.85

Financials

Year Year TTM 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Rev. Revenue N/A $464.37M $250.31M $83.80M $22.81M $0.06M $0.00M $0.25M $0.33M $0.09M $0.58M $2.74M
GM % Gross Margin % 54.05% 53.94% 38.01% -15.60% -,196.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
OM Operating Margin -41.10% -34.32% -,105.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Earnings Per Share $-1.63 $-1.46 $-2.72 $-3.50 $-3.23 $-2.68 $-2.84 $-2.12 $-2.69 $-2.91 $-1.07 $-1.56
Div. Dividends N/A $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
PR % Payout Ratio % 0 -0.00% -0.00% -0.00% -0.00% 0 0 0 0 0 0 0
Sha. Shares N/AM 96.81M 95.28M 93.59M 80.92M 66.13M 55.12M 54.68M 43.41M 43.21M 34.93M 29.22M
OCF Operating Cash Flow N/A $-,108.24M $-,270.19M $-,259.54M $-,230.07M $-,127.98M $-,118.17M $-80.49M $-91.26M $-,102.28M $-22.81M $-22.59M
FCF Free Cash Flow N/A $-,160.85M $-,270.96M $-,259.87M $-,203.06M $-,128.09M $-,118.56M $-81.22M $-91.31M $-,103.14M $-22.82M $-22.62M
FCFS Free Cash Flow Per Share $-1.69 $-1.30 $-2.88 $-3.20 $-3.27 $-2.33 $-2.17 $-1.76 $-2.11 $-2.86 $-0.80 $-1.31